Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: monoclonal antibody therapeutics - Integral molecular

Next Previous
Drug Profile

Research programme: monoclonal antibody therapeutics - Integral molecular

Latest Information Update: 12 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Integral Molecular
  • Class Analgesics; Antihyperglycaemics; Antivirals; Hepatoprotectants; Monoclonal antibodies
  • Mechanism of Action Cannabinoid receptor CB1 antagonists; GLUT4 stimulants; Immunomodulators; Membrane protein modulators; Purinergic P2X3 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Metabolic disorders; Pain

Highest Development Phases

  • Research Chikungunya virus infections; Dengue; Ebola virus infections; Hepatitis C; Zika virus infection
  • No development reported Metabolic disorders; Neuropathic pain; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus

Most Recent Events

  • 12 Oct 2023 Research programme: monoclonal antibody therapeutics - Integral molecular is available for licensing as of 10 Oct 2023. https://www.integralmolecular.com/partnering/
  • 05 Oct 2023 Early research development in Ebola-virus-infections, Chikungunya-virus-infections and Zika-virus-infection is still ongoing in USA (Parenteral) (Integral Molecular pipeline, October 2023)
  • 28 Jan 2023 No recent reports of development identified for research development in Metabolic-disorders in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top